Kane Biotech Inc has seen limited movement in its stock price recently, with no significant news emerging this week.
Kane Biotech Inc (KNE.V) has maintained a steady price point of C$0.03, reflecting a lack of significant market activity. Despite a recent partnership and ongoing developments, the stock has not seen notable fluctuations in the short term, with performance metrics indicating a challenging landscape for the company.
Investor takeaway: Investors should be aware of Kane Biotech's recent partnership to expand its market presence, though the stock's performance remains subdued amidst broader market challenges.
Advertisement
Kane Biotech Inc
KNE.V
KNE.V
Kane Biotech Inc
WealthAwesomeMarket cap
$5.13M
52W high
$0.05
52W low
$0.02
1W change
+0.00%
Beta
0.31
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on KNE's historical volatility
30-Day Vol
227.3%
Annualized
90-Day Vol
172.3%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.02
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.02 | C$0.01 – C$0.05 |
| 60 trading days | C$0.02 | C$0.01 – C$0.07 |
| 90 trading days | C$0.02 | C$0.01 – C$0.08 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Kane Biotech Inc's stock remains stagnant at C$0.03.
The stock is currently 17% of its 52-week trading range, indicating limited volatility and interest.
Bull case
The recent partnership with Ontario Medical Supply Inc. could improve Kane Biotech's market reach and potentially lead to increased revenue in the future.
Bear case
Kane Biotech's stock has dropped 37.50% year-to-date, and its financial metrics show ongoing challenges in profitability and growth, making it a risky investment.
Price Action Overview
Advertisement
Kane Biotech Inc's stock price has remained unchanged at C$0.03 for the past week, marking a 0.00% change in the last day. Over the past month, the stock has declined by 16.67%, with a significant year-to-date drop of 37.50%. This stagnation in price comes amidst limited trading activity, with the latest volume at 43,200 shares, about 67% of the 20-day average volume of 199,032 shares.
Recent Company Developments
Despite the recent lack of major news, Kane Biotech has made strides in expanding its commercial reach. On September 2, 2026, the company announced a partnership with Ontario Medical Supply Inc. to enhance its presence in the Canadian market. This collaboration aims to boost the distribution of its products, particularly the revyve® wound gel, which has been a focal point for the company. Additionally, Kane Biotech's financial results for Q2 2026 were released on August 27, 2026, detailing early-stage commercialization efforts.
Technical Picture
From a technical perspective, Kane Biotech's stock is currently trading below both its 50-day moving average of C$0.03 and its 200-day moving average of C$0.04, indicating a bearish trend. The stock has a beta of 0.31, suggesting lower volatility compared to the broader market. The 52-week trading range for KNE.V is between C$0.02 and C$0.05, placing the current price at 17% of this range, reflecting limited price movement.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
